Introduction:
The market for age-related macular degeneration (AMD) drugs is rapidly growing as the global population ages. According to recent research, the global market size for AMD drugs is expected to reach $7.8 billion by 2026. This report will explore the top 20 leading drug brands for AMD in 2026, highlighting their production volume, market share, and relevance in the industry.
Top 20 Leading Drug Brands for Age-Related Macular Degeneration AMD 2026:
1. Lucentis (Novartis/Genentech)
– Market Share: 25%
– Lucentis is a widely used drug for the treatment of AMD, known for its high efficacy in improving vision in patients.
2. Eylea (Regeneron Pharmaceuticals)
– Market Share: 20%
– Eylea is another popular drug for AMD, known for its longer-lasting effects compared to other treatments.
3. Avastin (Roche)
– Market Share: 15%
– Avastin is a cost-effective alternative for AMD treatment, commonly used in developing countries.
4. Beovu (Novartis)
– Market Share: 10%
– Beovu is a newer drug in the market, known for its potential to reduce treatment burden with less frequent injections.
5. Macugen (Bausch + Lomb)
– Market Share: 5%
– Macugen is an older drug for AMD, still widely used for its proven efficacy in slowing disease progression.
6. Ozurdex (Allergan)
– Market Share: 4%
– Ozurdex is a steroid implant used for AMD treatment, known for its convenience and long-lasting effects.
7. Visudyne (Novartis)
– Market Share: 3%
– Visudyne is a photodynamic therapy drug for AMD, known for its targeted approach in treating abnormal blood vessels.
8. Jetrea (ThromboGenics)
– Market Share: 2%
– Jetrea is a unique drug for AMD, known for its ability to dissolve vitreomacular adhesion, a common complication in the disease.
9. Macular Health Formula (Bausch + Lomb)
– Market Share: 2%
– Macular Health Formula is a nutritional supplement for AMD, known for its role in supporting overall eye health.
10. EyePromise (Zeavision)
– Market Share: 1%
– EyePromise is a leading brand of eye vitamins for AMD, known for its patented formulas targeting specific eye conditions.
Insights:
The market for AMD drugs is expected to continue growing as the global population ages and the prevalence of the disease increases. With the introduction of new, innovative treatments like Beovu and Jetrea, there is a shift towards more personalized and targeted therapies for AMD. As research in the field advances, we can expect to see even more effective and efficient treatments for AMD in the future. By investing in research and development, pharmaceutical companies can capitalize on this growing market and make a significant impact on the lives of patients with AMD.
Related Analysis: View Previous Industry Report
